2021 Fiscal Year Final Research Report
Serin-protease inhibitor prevents renal dysfunction after ischemia-reperfusion injury
| Project/Area Number |
20K17720
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55030:Cardiovascular surgery-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | 急性下肢虚血 / 虚血再灌流障害 / ナファモスタットメシル酸 |
|---|
| Outline of Final Research Achievements |
Ischemia-Reperfusion injury (IRI) after revascularization for acute limb ischemia often causes severe systemic organ damage, e.g. acute respiratory failure, acute renal dysfunction and compartment syndrome. Pathology of IRI is related with reactive oxygen species, oxidative stress, and activation of white blood cells. We tried to reveal Nafamostat mesylate (NM) prevents the organ damages after IRI.
In this study, we estimated mouse limb ischemia and reperfusion model. Then, in 3 groups: sham operation group, ischemia and reperfusion group (IM), and IM with NM administration group (IR+NM), we measured serous chemistry. The result is that AST and ALT significantly improved by NM administration. Whereas, BUN, serous creatinine, creatinine kinase and serous potassium did not significantly change between IR group and IR+NM group. This result suggested that NM inhibit lever dysfunction after IRI. This is the basic of further study to reveal the effect of IRI depression of NM.
|
| Free Research Field |
医学
|
| Academic Significance and Societal Importance of the Research Achievements |
今回の我々の検証により、ナファモスタットメシル酸が急性下肢虚血後の再灌流障害に対して肝障害を改善する改善効果を有することが明らかとなった。一方で腎障害・筋組織障害に対する改善効果は今回のモデルで示すことができなかった。しかしながら、今回の検証により部分的ながらナファモスタットメシル酸が再灌流障害に対する臓器保護効果を有することが示唆されたことは、今後、マウスモデルやナファモスタットメシル酸の投与法を再検討することにより、腎障害・筋組織障害に対するナファモスタットメシル酸の抑制効果を検証するための足掛かりとなったと考える。
|
